Meeting Summary 

For the OCT for DME talk

OCT is an effective non-invasive diagnostic tool that can diagnose and monitor patients with DME and diabetic retinopathy. It provides high-resolution cross-sectional images of the macula, which helps to detect, measure, and locate DME. The presentation emphasized the importance of using OCT in tracking the treatment response and follow-up prognosis to improve patient outcomes.

For the FFA for Diabetic Retinopathy and DME talk

FFA is a powerful diagnostic tool that can help evaluate the blood flow status of both the macula and the retina's periphery. It produces informative images of the dynamic flow of retinal vessels, which can aid in detecting and localizing microvascular leaks and ischemic changes at the macula. This, in turn, helps locate subtle neovascularization, IRMA, and peripheral ischemic changes, all of which can affect our treatment plan.

For the DME management talk

In recent years, significant advancements have been made In the management of Diabetic Macular Edema (DME), opening up new possibilities for patients with this condition.

These emerging breakthroughs include innovative treatment options, such as anti-vascular endothelial growth factor (anti-VEGF) therapies and corticosteroid implants, which have shown promising results in improving visual outcomes.

With these advancements, the future of DME management is looking brighter, providing hope for a better quality of life for those affected by this sight-threatening condition.

Management of DME Improving with new molecules concerning BCVA, CRT, Durability & Safety

We are still in need of better and optimal medications to treat DME

The availability of different molecules for treating DME gives us the capability of selecting suitable molecules for the patient

For the Diabetic retinopathy management talk

It is crucial to determine the stage of diabetic retinopathy during the clinical examination before deciding on the treatment. Mild to moderate NPDR may only require follow-up, but very severe NPDR to high-risk PDR may need PRP treatment as it is highly effective. However, anti-VEGF treatment can be beneficial, especially when combined with DME or in cases of high-risk PDR.

For diabetic vitreous hemorrhage medical management talk

When diabetic patients experience vitreous hemorrhage, it is important to perform a clinical examination and questionnaire to rule out any peripheral retinal lesion and document previous ocular treatments. B-scan evaluation and OCT are also necessary to assess the case and determine the appropriate management plan accurately. Medically, vitreous hemorrhage should be treated with PRP, if the fundus view permits. However, if there is no TRD and laser application is not possible, or if there is DME, then anti-VEGF can be used to clear up the hemorrhage and manage any co-existing DME. On the other hand, if the case is associated with RD, then PPV is the main treatment of choice.

EXPLORE MORE